{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-081604","form_type":"8-K","ticker":"REVB","cik":"0001810560","company_name":"REVELATION BIOSCIENCES, INC.","filed_at":"2025-06-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.820292+00:00","generated_at":"2026-05-20T00:08:53.029064+00:00","sec_items":["1.01","3.03","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Revelation Biosciences closes $4M public offering of common stock and warrants","bullets":["Gross proceeds ~$4M from sale of 3,640,000 shares (or pre-funded warrants) plus warrants for up to 14,560,000 shares.","Warrants exercise price $1.10/share, exercisable after stockholder approval, expire 5 years from initial exercise date.","Net proceeds to fund Phase 1b study, clinical drug supply manufacture, preclinical work, and general corporate purposes.","Roth Capital Partners acted as sole placement agent; offering closed May 29, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-081604","json":"https://secwatch.observer/filing/0000950170-25-081604.json","markdown":"https://secwatch.observer/filing/0000950170-25-081604.md","text":"https://secwatch.observer/filing/0000950170-25-081604.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1810560/000095017025081604/0000950170-25-081604-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1810560/000095017025081604/revb-20250528.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-20T00:08:53.029064+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}